Lung Therapeutics

Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The Company is currently developing a drug technology, LTI-03, for the treatment of Idiopathic Pulmonary Fibrosis. Preclinical evidence suggests that LTI-03 sustains survival of damaged lung cells throughout this novel mechanism of action, in addition to slowing and resolving the downstream progress of fibrosis.

Company Growth (employees)
Austin, US
Size (employees)
10 (est)
Lung Therapeutics was founded in 2013 and is headquartered in Austin, US

Lung Therapeutics Office Locations

Lung Therapeutics has an office in Austin
Show all (1)

Lung Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$17.9 m

Latest funding size

$14.3 m

Time since last funding

9 months


Lung Therapeutics's latest funding round in June 2017 was reported to be $14.3 m. In total, Lung Therapeutics has raised $17.9 m

Lung Therapeutics's Web-traffic and Trends

Lung Therapeutics Online and Social Media Presence

Lung Therapeutics Company Life and Culture

You may also be interested in